No Flash

Therapeutics

Developing drugs that target novel biological pathways

Learn More

Bioprocessing

Products to enhance manufacturing efficiency and economics

Learn More

Highlights

  • June 9, 2010: Repligen Reports Fourth Quarter and Fiscal Year 2010 Financial Results MoreSmall orange arrow
  • May 27, 2010: Repligen Announces FDA and EMA Approval of Re-analysis of Images from Phase 3 Trial of RG1068 for Pancreatic Imaging MoreSmall orange arrow
  • May 24, 2010: Repligen Receives Orphan Drug Designation for RG2833 for Friedreich's ataxia MoreSmall orange arrow
  • View All